Add to balance / Manage account | User: | Log out |
Prospect News home > News index > List of issuers E > Headlines for European Medco Development 4 Sarl > News item |
PharmaZell revises €215 million term loan B OID to 99.25
By Sara Rosenberg
New York, Nov. 5 – PharmaZell (European Medco Development 4 Sarl) tightened the original issue discount on its fungible €215 million add-on covenant-lite term loan B due May 2027 (B2/B-/B+) to 99.25 from revised talk in the range of 98.75 to 99 and initial talk of 98.5, according to a market source.
Pricing on the add-on term loan is Euribor plus 400 basis points with a 0% floor.
The add-on and existing term loans are getting 101 soft call protection for six months.
Credit Suisse and HSBC are the physical bookrunners on the deal. Investec, Jefferies and UniCredit are joint bookrunners.
Proceeds will be used to help fund the €765 million acquisition of Novasep and related fees and expenses.
Pro forma for the transaction, the term loan B will total €520 million.
Bridgepoint is the sponsor.
PharmaZell is a Germany-based manufacturer of niche active pharmaceutical ingredients. Novasep is a France-based provider of services in the field of molecule production and purification for the life science and chemical industries.
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.